A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer
A phase 1/2 trial of Capecitabine in colorectal cancer, run by BeyondBio Inc., now recruiting.
Overview
A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer is a phase 1/2 interventional study registered as NCT05093907 by BeyondBio Inc., with 27 participants planned, started 2021-08-31 and due to reach its primary completion in 2026-11-30. Interventions recorded: BEY1107, Capecitabine. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.
Shares Capecitabine, Colorectal cancer.
- TrialSHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer
Shares Capecitabine, Colorectal cancer.
- TrialAn Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Shares Capecitabine, Colorectal cancer.
- TrialA Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
Shares Capecitabine, Colorectal cancer.
- TrialA Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Can
Shares Capecitabine, Colorectal cancer.
- TrialA Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
Shares Capecitabine, Colorectal cancer.
- TrialNeoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
Shares Capecitabine, Colorectal cancer.
- TreatmentDoxifluridine
Shares Capecitabine, Colorectal cancer.